Manila Times Business
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success
Artelo’s lead medicinal chemist reveals findings at the Royal Society of Chemistry-BMCS/DMDG Medicinal Chemistry Conference in London SOLANA BEACH, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo” or the "Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, announces that Myles Osborn, Lead Medicinal Chemist
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Cellebrite Launches the New Age of Investigations with Genesis, Now Generally Available
Just now
Adaptive ML and AT&T Expand AI Collaboration to Scale Specialized Models Across Enterprise Workflows
Just now
LEIFRAS Co., Ltd. Announces Entry into Kawasaki City Through New School Club Support Contract
Just now
TOYO Co., Ltd. Secures Two Major Supply Agreements Totaling $185.6 Million in Cumulative Purchase Orders for the U.S. Market
Just now